CARTITUDE-2 Cohort A: Updated Clinical Data on Cilta-Cel Presented at ASCO 2022

Prof. Hermann Einsele Provides Updates on Clinical Data of Cilta-Cel in CARTITUDE-2 Cohort A among Progressive Myeloma Patients

Abstract Title:

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.

In this video:

Prof. Hermann Einsele (University of Würzburg—Würzburg, Germany) discusses updated clinical data of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy (LOT) for CARTITUDE-2 Cohort A at ASCO 2022.

What is the purpose of this trial? 

Cohort A of the multicohort phase 2 CARTITUDE-2 study is evaluating ciltacabtagene autoleucel (cilta-cel) safety and efficacy in multiple myeloma patients who received 1–3 prior line of therapy (LOT) and were lenalidomide-refractory – a difficult-to-treat population with poor prognosis. Updated results presented.

Conclusion:

At a longer median follow-up (MFU) of 17.1 months, a single cilta-cel infusion led to deepening and durable responses in patients with MM who had 1–3 prior lines of therapy (LOT) and were lenalidomide-refractory. Follow-up is ongoing. Updated and in-depth pharmacokinetic (PK), cytokine, and CAR T subset analyses and clinical correlation will be presented and will provide novel insights into biological correlates of efficacy and safety in this patient population. This patient population is being further evaluated in the CARTITUDE-4 study (NCT04181827), which has concluded enrollment.

Clinical trial information: NCT04133636 (https://clinicaltrials.gov/ct2/show/NCT04133636)